NCI Trials for June 2021

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.  

For further information, contact the principal investigator listed.

Phase I – 10347

A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and SÈzary Syndrome (SS)

Yale University Cancer Center LAO

Mehta-Shah, Neha

(314) 747-7402

Phase I – 10450

A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Ohio State University Comprehensive Cancer Center LAO

Chauhan, Aman

(504) 278-0134

Phase II – A051902

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Alliance for Clinical Trials in Oncology

Mehta-Shah, Neha

(314) 747-7955

Phase III – ANHL1931

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Children’s Oncology Group

Roth, Lisa Giulino

(212) 746-3400

Phase III – EAA171

Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

ECOG-ACRIN Cancer Research Group

Kumar, Shaji K.

(507) 284-5096

Phase Other – AMC-113

Observational Cohort Study of People Living with HIV Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies

AIDS Malignancy Consortium

Barta, Stefan Klaus

(215) 615-6506

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login